Tixagevimab/AZD8895 represents a unique treatment method utilizing paired monoclonal immunoglobulins. Specifically, these medications work by selectively attaching to the receptor-binding domain of the SARS-CoV-2 https://www.targetmol.com/compound/tixagevimab